Oric Pharmaceuticals Increases Inducement Equity Plan Shares

Oric Pharmaceuticals' Board of Directors approved an amendment to its 2022 Inducement Equity Incentive Plan, increasing the shares reserved for issuance. An additional 1,100,000 shares were added, bringing the total to 3,350,000 shares. This action was taken without stockholder approval, in accordance with applicable Nasdaq Listing Rules, to facilitate the granting of equity awards to new employees as an inducement for employment.